Ocular hypotensive and vasodilative effects of two beta-adrenergic blockers with intrinsic sympathomimetic activity.
OBJECTIVE
The ocular hypotensive and vasodilative effects of vaninolol and eugenolol, two beta-adrenergic blockers with intrinsic sympathomimetic activity, were tested in rabbits and their pharmacologic mechanisms were also studied in vitro.


METHODS
Intraocular pressure was measured in ocular hypertonic rabbits which were induced by infusing 20% NaCl or 5% glucose solution. The rabbit's ocular blood flow was determined using the colored microsphere technique. The concentrations of cAMP were evaluated in porcine ciliary body and cultured A7r5 smooth muscle cells by radioimmunoassay. Ca+2 concentration was measured in A7r5 cells by spectrofluorometry after loading cells with Fura-2-AM.


RESULTS
It was found that 0.5% eugenolol and vaninolol could suppress the intraocular pressure in glucose-induced ocular hypertensive rabbits and delay the intraocular pressure recovery in NaCl-induced ocular hypertensive rabbits. In addition, both agents improved the ocular blood flow in the iris, ciliary body, retina and choroid. Vaninolol and eugenolol of 10 microM inhibited the basal cAMP accumulation from 23.9 +/- 2.0 of control to 8.7 +/- 0.4 and 2.4 +/- 0.1 respectively and inhibited the isoproterenol-induced cAMP accumulation from 154.3 +/- 13.6 to 120.6 +/- 8.3 and 74.2 +/- 6.1 respectively in the porcine ciliary body. The cellular cAMP concentration was significantly increased from 10 +/- 1 of control to 96 +/- 5 (vaninolol) and 38 +/- 3 (eugenolol) in cultured A7r5 smooth muscle cells. Both agents also increased the intracellular calcium concentration in A7r5 cells.


CONCLUSIONS
These results indicate that the lowering of intraocular pressure by vaninolol and eugenolol may be due to cAMP suppression in the ciliary body by beta-antagonist and/or alpha2-agonist activities. Both agents cause vasodilation via beta2-agonist action that increase the smooth muscle cellular cAMP level more than vasoconstriction via alpha-agonist activity by increasing an influx of extracellular Ca+2.
Hong
S J
SJ
Department of Pharmacology, Kaohsiung Medical College, Taiwan, ROC. hong6657@ms5.hinet.net
Wu
K Y
KY
Chen
I J
IJ
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001011:Aorta / Q000166:cytology / Q000378:metabolism; D002074:Butanones / Q000494:pharmacology*; D002460:Cell Line; D002924:Ciliary Body / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D005054:Eugenol / Q000031:analogs & derivatives / Q000494:pharmacology*; D005123:Eye / Q000098:blood supply; D005947:Glucose / Q000494:pharmacology; D007275:Injections, Intravenous; D007429:Intraocular Pressure / Q000187:drug effects; D007545:Isoproterenol / Q000494:pharmacology; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000378:metabolism; D009798:Ocular Hypertension / Q000503:physiopathology*; D011412:Propanolamines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D013552:Swine; D013566:Sympathomimetics / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D000319:Adrenergic beta-Antagonists; D002074:Butanones; D011412:Propanolamines; D013566:Sympathomimetics; D014665:Vasodilator Agents; C088562:vaninolol; D005054:Eugenol; D000242:Cyclic AMP; D005947:Glucose; D007545:Isoproterenol